|
|
|
Insider
Information: |
Clague Laura |
Relationship: |
Director |
City: |
San Diego |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
424,757 |
|
Indirect Shares
|
2,000 |
|
|
Direct
Value |
$1,037,526 |
|
|
Indirect Value
|
$3,800 |
|
|
Total
Shares |
426,757 |
|
|
Total
Value |
$1,041,326 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
3
|
Stock
price went up :
|
0
|
1
|
Stock
price went down : |
0
|
2
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
-32.4%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Genasys Inc |
GNSS |
Director |
2022-04-27 |
284,311 |
2022-04-27 |
2,000 |
Premium* |
|
Travere Therapeutics, Inc |
TVTX |
Chief Financial Officer |
2022-05-11 |
35,655 |
2018-02-08 |
0 |
Premium* |
|
Fluidigm Corp |
FLDM |
Director |
2023-06-14 |
104,791 |
2018-10-30 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
65 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 3
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2021-08-13 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
32,723 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2021-08-17 |
4 |
S |
$17.12 |
$24,085 |
D/D |
(1,407) |
31,316 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2022-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
38,816 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2022-01-11 |
4 |
AS |
$27.40 |
$205,500 |
D/D |
(7,500) |
31,316 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2022-01-24 |
4 |
AS |
$24.98 |
$51,534 |
D/D |
(2,063) |
29,253 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2022-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
9,840 |
39,093 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2022-01-31 |
4 |
AS |
$27.40 |
$33,921 |
D/D |
(1,238) |
37,855 |
0 |
% |
|
GNSS |
Genasys Inc |
Director |
|
2022-02-23 |
4 |
S |
$3.14 |
$43,068 |
D/D |
(13,716) |
204,311 |
0 |
% |
|
GNSS |
Genasys Inc |
Director |
|
2022-02-23 |
4 |
OE |
$2.16 |
$43,200 |
D/D |
20,000 |
218,027 |
0 |
- |
|
GNSS |
Genasys Inc |
Director |
|
2022-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
234,311 |
0 |
- |
|
GNSS |
Genasys Inc |
Director |
|
2022-04-27 |
4 |
OE |
$1.33 |
$66,500 |
D/D |
50,000 |
284,311 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2022-05-10 |
4 |
AS |
$21.51 |
$17,746 |
D/D |
(825) |
37,030 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2022-05-11 |
4 |
AS |
$21.51 |
$29,576 |
D/D |
(1,375) |
35,655 |
0 |
% |
|
FLDM |
Fluidigm Corp |
Director |
|
2022-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
30,914 |
78,415 |
0 |
- |
|
FLDM |
Fluidigm Corp |
Director |
|
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
26,376 |
104,791 |
0 |
- |
|
65 Records found
|
|
Page 3 of 3 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|